Reuters logo
7 months ago
BRIEF-Arbutus provides additional data from the ARB-1467 phase II clinical trial in HBV patients
December 12, 2016 / 9:10 PM / 7 months ago

BRIEF-Arbutus provides additional data from the ARB-1467 phase II clinical trial in HBV patients

1 Min Read

Dec 12 (Reuters) - Arbutus Biopharma Corp :

* Arbutus Biopharma - one patient in cohort 2 discontinued treatment due to transient elevation of transaminases with normal bilirubin observed

* Arbutus Biopharma Corp - company plans to add another cohort to ARB-1467 study to explore bi-weekly administration of 0.4 mg/kg dose

* Arbutus Biopharma Corp - complete cohort 1 and 2 ARB-1467 multi-dose data demonstrate dose-responsive hbsag reductions

* Arbutus Biopharma Corp - treatment with arb-1467 has been generally well tolerated in this study to date

* Arbutus provides additional data from the ARB-1467 phase ii clinical trial in HBV patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below